


May, 2017, Vol 4, No 5

# MSD

Medical Science & Discovery



Evaluation of factors that affecting mortality in urgent redo-laparotomies

International Journal of  
Medical Science and Discovery  
Open Access Scientific Journal  
ISSN: 2148-6832  
Lycia Press LONDON U.K.  
[www.medscidiscovery.com](http://www.medscidiscovery.com)



Medical Science and Discovery (<http://www.medscidiscovery.com>) is an international open access, peer-reviewed scientific research journal that provides rapid publication of articles in all disciplines of human health, clinical and basic medical science such as Biophysics, Biochemistry, Histology, Physiology, Genetics, Pathology, Toxicology, Anatomical Sciences, Pharmacology, Embryology, Internal and Surgical Medicine.

The policy of top priority of MSD is to put forward and highlight medical innovations and inspiring patents.

MSD offers an exceptionally fast publication schedule including prompt peer-review by the experts in the field and immediate publication upon acceptance. The editorial board aims at reviewing the submitted articles as fast as possible and promptly including them in the forthcoming issues.

This journal is published under ethical publishing policy of international scientific Bioethics and publication rules.

MSD supports the Open Access Initiative. Abstracts and full texts (HTML and PDF format) of all articles published by MSD are freely accessible to everyone immediately upon publication.

Medical Science and Discovery has scientific affiliation with Lycia Clinics London UK

**Indexed Databases:** NLM Catalog, Chemical Abstracts (CAS), Index Copernicus, Open Air, ULRICHS Database, Proquest, Advanced Science Index, Turkish Citation Index, Tubitak Ulakbim, Research Bible, Scholar Google

**Medical Science and Discovery is an international open access, peer-reviewed scientific research journal.**

**ISSN: 2148-6832 (Print) E-ISSN: 2148-6832 (Online)**

**Category: Multi Disciplinary Health Science Journal**

**Abbreviated key title: Med. Sci. Discov.**

**Frequency: Monthly**

**Review System: Double Blind Peer Review**

**Circulation: Globally, Online, Printed**

**Article Processing Charge (APC): US\$ 100**

**Licensing: CC-BY-NC 4.0 International License Environmental**

**Editor-in-Chief: Assoc. Prof. Dr. Dr. Asghar Rajabzadeh, Anatomical Department, Lorestan University of Medical Sciences, Khorramabad, Iran**

**Established: 30.04.2014**

**Web address: [www.medscidiscovery.com](http://www.medscidiscovery.com); <http://dergipark.ulakbim.gov.tr/msd>**

**E-mail : [editor \[at\] medscidiscovery.com](mailto:editor[at]medscidiscovery.com)**

**Phone : +44 020 3289 9294**

**Design and preparation of PDFs, Language editing, Web site design, Graphical design Services of international Journal of Medical Science and Discovery has been contracted with Lycia Press LONDON, UK (as Publisher), by the MSD Board of Directors**

**Publisher: Lycia Press Inc.**

**Address: 3rd Floor 86 - 90 Paul Street, EC2A 4NE, London, UK**

**Web address: [www.lycians.com](http://www.lycians.com)**

**Phone : +44 020 3289 9294**

**E-mail : [office \[at\] lycians.com](mailto:office[at]lycians.com)**

**E-mail : [info \[at\] lycians.com](mailto:info[at]lycians.com)**

## Editorial Board of Medical Science and Discovery

### Honorary Editors

Prof. Dr.	Aziz Sancar	UNC, Faculty of Medicine, Dept. of Biochemistry-Biophysics, Chapel Hill, NC, USA
Prof. Dr.	Giancarlo BAROLAT	Barolat Institute, 1721 E 19th Ave #434, Denver, CO 80218, USA
Prof. Dr.	Joyce REARDON	UNC, Faculty of Medicine, Dept. of Biochemistry-Biophysics, Chapel Hill, NC, USA
Prof. Dr.	Metin TULGAR	Yuzuncu Yil University, School of Medicine, Dept. of Biophysics, Van, TR

### Deputy Editors

Assoc. Prof.	Michael George KEMP	UNC, 120 Mason Farm Road, Campus Box 7260, Genetic Medicine Bldg Room 3010 Chapel Hill, NC 27599 USA
Assoc. Prof.	Zafer Akan (Founder)	Lycia Press Inc., 3rd Floor 86 - 90 Paul Street, EC2A 4NE, London, UK

### Internal Medicine

Asist. Prof. Dr.	Ahmet YILMAZ	Dicle University, Faculty of Medicine, Dept. of Family Medicine
Prof. Dr.	Ali Rıza BILGE	CBU, Faculty of Medicine, Dept. of cardiology, Manisa, TR
Assoc. Prof. Dr.	Alparslan SAHİN	Dicle University, Faculty of Medicine, Dept. of Eye
Prof. Dr.	Ayşe YÜKSEL	Arel University, Faculty of Medicine, Dept. of Public Health, Istanbul
Assoc. Prof. Dr.	Bekir Serhat YILDIZ	PAU, Faculty of Medicine, Dept. of Cardiology, Denizli, Turkey
Prof. Dr.	Hatice Sınav USLU	ISMU, Faculty of Medicine, Dept. of Nucleer Medicine, Istanbul, TR
Prof. Dr.	Hikmet YILMAZ	CBU, Faculty of Medicine, Dept. of Neurology, Manisa, TR
Prof. Dr.	Hulya Ozdemir	YYU Faculty of Medicine, Dept. of Pharmacology, Van
Assoc. Prof. Dr.	Huseyin GUDUCUOGLU	YYU Faculty of Medicine, Dept. of Microbiology, Van
Asist. Prof. Dr.	Murat ÖZSARAÇ	CBU, Faculty of Medicine, Dept. of Emergency Medicine
Prof. Dr.	Muzaffer POLAT	CBU, Faculty of Medicine, Dept. of Pediatric Neurology
Assist. Prof. Dr.	Nesrin CEYLAN	Ankara Children's Health, Training and Research Hospital, Department of Hematology Oncology , Ankara, Turkey
Prof. Dr.	Nobuo INOTSUME	Hokkaido Pharmaceutical University, Clinical Pharmacology, Hokkaido AC, JAPAN
Assist Prof. Dr.	Secil ILHAN YILMAZ	Erciyes University, Genom and Stem Cell Research Center, Kayseri, TR
Prof. Dr.	Talat ECEMIS	CBU, Faculty of Medicine, Dept. of Microbiology, Manisa, TR

### Surgical Medicine

Assoc. Prof. Dr.	Abdullah BOYUK	Dicle University, Faculty of Medicine, Dept. of General Surgery
Assist. Prof. Dr.	Christopher Schmitt	University of California, San Francisco Cardiovascular Res. Inst.
Prof. Dr.	Çetin DİNÇEL	Hacettepe University, Faculty of Medicine, Dept. of Urology
Prof. Dr.	Cuneyt Temiz	CBU, Faculty of Medicine, Dept. of Neurosurgery, Manisa
Prof. Dr.	Gönül Tezcan KELEŞ	CBU, Faculty of Medicine, Dept. of Anesthesiology and Rean.
Prof. Dr.	M. Derya BALBAY	Memorial Hospital, Dept. of Urooncology
Assoc. Prof. Dr.	Mustafa USLU	Duzce University, Faculty of Medicine, Dept. of Orthopedics, Bolu
Asist. Prof. Dr.	Murat YILDIR	BAU Faculty of Medicine, Dept. of General Surgery
Prof. Dr.	Nasuhi Engin AYDIN	Katip Çelebi University, Faculty of Medicine, Dept. of Pathology
Assist. Prof. Dr.	Pinar SOLMAZ HASDEMİR	CBU, Faculty of Medicine, Dept. of Obstetrics and Gynecology, Manisa
Assoc. Prof. Dr.	Tevfik GUNES	PAU, Faculty of Medicine, Dept. of Cardiovascular Surgery, Denizli,
Assoc. Prof. Dr.	Yusuf Izzettin ALIHANOGLU	PAU, Faculty of Medicine, Dept. of Cardiology, Denizli

## Editorial Board of Medical Science and Discovery

### Basic Sciences

Dr.	Alper Tunga ÖZDEMİR	Manisa ME State Hospital Dept. of Medical Biochemistry
Prof. Dr.	Alev Meltem ERCAN	Istanbul University, Cerrahpasa Medical Faculty, Dept. of Biophysics, Istanbul
Assoc. Prof. Dr.	Anzel BAHADIR	Duzce University, Faculty of Medicine, Dept. of Biophysics, Bolu, TR
Assoc. Prof. Dr.	Ayşe Inhan GARIP	Marmara University, Faculty of Medicine, Dept. of Biophysics
Assoc. Prof. Dr.	Bahriye SİRAN	Gazi University, Faculty of Medicine, Dept. of Biophysics
Prof. Dr.	Beki KAN	Acibadem University, Faculty of Medicine, Dept. of Biophysics
Prof. Dr.	Cevval ULMAN	CBU, Faculty of Medicine, Dept. of Biochemistry, Manisa, TR
Assoc. Prof. Dr.	Gokhan OTO	YYU Faculty of Medicine, Dept. of Pharmacology, Van, TR
Prof. Dr.	Halit DEMİR	YYU Faculty of Science, Dept. of Biochemistry
Prof. Dr.	Hasan YILMAZ	YYU Faculty of Science, Dept. of Parasitology, Van, TR
Prof. Dr.	M. Ali KÖRPINAR	Istanbul University, Cerrahpasa Medical Faculty, Dept. of Biophysics, Istanbul
Prof. Dr.	Mustafa ÖZBEK	CBU, Faculty of Medicine, Dept. of Physiology
Prof. Dr.	Nobuo Inotsume	Hokkaido Pharmaceutical Univ., Clinical Pharmacology, Hokkaido AC, JAPAN
Asist. Prof. Dr.	Özdemirhan Serçin	Interdisciplinary Research Institute, Université Libre de Bruxelles, Belgium
Prof. Dr.	Seda VATANSEVER	CBU, Faculty of Medicine, Dept. of Histology and Embryology
Prof. Dr.	Sevinç İNAN	CBU, Faculty of Medicine, Dept. of Histology and Embryology
Asist. Prof. Dr.	Shoban GADDAMADI	Washington State University College of Pharmacy, Dept. of Experimental and Systems Pharmacology, Spokane, WA, USA
Asist. Prof. Dr.	Tahir ÇAKIR	YYU Faculty of Medicine, Dept. of Nuclear Medicine Van, TR
Assoc. Prof. Dr.	Tamer ZEREN	CBU, Faculty of Medicine, Dept. of Biophysics
Prof. Dr.	Tunaya KALKAN	Istanbul University, Cerrahpasa Medical Faculty, Dept. of Biophysics, Istanbul
Assist Prof. Dr.	Younes El Bouzekri EL IDRİSSI	Place Aboubakr, Imm 22, App 6, Bd Fal ould oumeir, Agdal Rabat
Assist Prof. Dr.	Yusuf Kemal DEMİR	Marmara University, Faculty of Pharmacy, Dept. of Pharmaceutical Tech. Istanbul TR

### Statistical Editor

Prof. Dr.	Siddık KESKİN	YYU Faculty of Medicine, Dept. of Medical Statistics, Van, TR
-----------	---------------	---

### Language Editor

Asist. Prof. Dr.	Hakan ERGİN	Istanbul University, Dept. of Foreign Languages, Istanbul, TR
------------------	-------------	---

### Editorial Office


General Coordinator	Elena JALBA	Office Lycia Press, London, UK
Typist-Compositor	Gonul OZGOK	Office Lycia Press, London, UK
Typist-Compositor	Bugra YOLDAS	Office Lycia Press, London, UK

## Instruction for Authors

- **Important**
- MSD is committed to deterring plagiarism, including self-plagiarism. Your manuscript will screen to compare for similarity with published articles.
- For research studies using human or animal subjects, the trial's design, conduct and reporting of results must conform to Good Clinical Practice guidelines (such as the Good Clinical Practice in Food and Drug Administration (FDA)-Regulated Clinical Trials (USA) or the Medical Research Council Guidelines for Good Clinical Practice in Clinical Trials (UK)) and/or to the World Medical Association (WMA) Declaration of Helsinki
- Dear Authors, please upload just these three files to the manuscript submission system
- [Title Page Sample](#)
- [Manuscript Sample](#)
- [Copyright Transfer and Author Consent Form](#)
- Please select Keywords from the MESH source
- (<https://www.nlm.nih.gov/mesh/MBrowser.html>)
- Manuscripts should be prepared in accordance with the "Uniform Requirements for Manuscripts Submission to Biomedical Journals" proclaimed by the International Committee of Medical Journal Editors ([www.icmje.org](http://www.icmje.org)).
- MSD uses Vancouver reference style, please prepare articles due to Vancouver reference style rules.
- **Manuscript Preparation Rules**
- **1. Cover letter**
- **a-** A statement that the manuscript has been read and approved by all the authors.
- **b-** That the requirements for authorship have been met for all the authors, based on the criteria stated by *ICMJE*.
- **c-** Approval of all the authors regarding the order in which their names have appeared.
- **d-** That each author confirms the manuscript represents honest work.
- **e-** The name, address, and telephone number of the corresponding author who is responsible for communicating with other authors about revisions and final approval.
- **f-** The letter should give any additional information that may be helpful to the editor, such as the type or format of the article. If the manuscript has been submitted previously to another journal or in another language, it is helpful to include the previous editor's and reviewers' comments with the submitted manuscript, along with the authors' responses to those comments. Submitting previous evaluatory review of another journal accelerates the review process.
- **g-** For accepted manuscripts, the authors are requested to fill and sign the journal's cover letter to express their consent for its publication.
- **h-** To reproduce published material, to use illustrations or tables or report information about identifiable people, the author should submit a copy of the permission with the manuscript to the journal.
- **2. Top Ethic Committee Approval**  
Inclusion of the approval letter from the relevant Ethics Committee or Institution's Review Board regarding the research protocol and the rights of the subjects (if applicable to the study)
- **3. Top Consent Form**  
Attach a copy of the consent form to the letter, if applicable. Consent forms would be evaluated by the Ethics Committee and then signed by the participant.
- **4. Top RCT or NCT Registration**  
Emailing the letter denoting registration of RCTs or NCTs in domestic or international databases (The trial's registration number needs to be mentioned, too).
- 5. Manuscripts submitted in English, must be type written, double-spaced, on good quality A4 paper, or paper of similar format. Authors are requested to reserve margins of at least 2.5cm all around the paper. Original drawings of photos, tables and figures should be furnished together with the manuscripts.
- 6. Manuscripts should be kept to a minimum length and should be subdivided into labeled sections (Title page, Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement, and References).
- 7. A title page is to be provided and should include the title of the article, authors' names with full first name (with degrees), authors' affiliation, suggested running title and corresponding author. The affiliation should comprise the department, institution (usually university or company), city and state (or nation). The suggested running title should be less than 50 characters (including spaces) and should comprise the article title or an abbreviated version thereof. For office purposes, the title page should include the name and complete mailing address, telephone and fax number, and email of the one author designated to review proofs.
- 8. An abstract no longer than 250 words for reviews and research articles is to be provided as the second page. Abstract should be structured as objective(s) (including purpose setting), materials and methods, results, and conclusion.

## Instruction for Authors

- **Case Report**
- A case report is a case study, case report, or other description of a case that should contain 1500 - 2000 words with a structured abstract of 200 words maximum. Case reports should comprise sections of Introduction, Case Presentation, and Conclusions in Abstract and Introduction, Case Presentation, and Discussion in full text with not more than 2 tables or figures and up to 20 references.
- **Brief Report**
- Brief Reports should contain 1000 - 2000 words with a structured abstract of 200 words maximum. Short reports should comprise sections of Background, Objectives, Materials & Methods, Results and Discussion with not more than 2 tables or figures and up to 20 references.
- **Short Communication**
- Short Communication, follow the instructions for original articles, except that the total word number of the main text (excluding references, tables and figure legends) is limited to 2000 with no more than 2 figures and/or tables and no more than 15 references. An abstract, not exceeding 150 words, should be presented at the beginning of the article.
- **News**
- News should contain 1000 - 2000 words with a structured abstract of 200 words maximum. News should comprise sections of Background, Objectives, Materials & Methods, Results and Discussion with not more than 2 tables or figures and up to 20 references.
- **Publication Policies**
- Manuscripts, or the essence of their content, must be previously unpublished and should not be under simultaneous consideration by another Journal. The authors should also declare if any similar work has been submitted to or published by another Journal. By virtue of the submitted manuscript, the corresponding author acknowledges that all the co-authors have seen and approved the final version of the manuscript. The corresponding author should provide all co-authors with information regarding the manuscript, and obtain their approval before submitting any revisions. Manuscripts are only accepted for publication on the understanding that the authors will permit editorial amendments, though proofs will always be submitted to the corresponding author before being sent finally to press. Prior to the initial submission of a new manuscript, please carefully consider that all authors' names are included as no change to authors' details will be permitted after the acceptance. The decision to accept a contribution rests with the Editorial Board of the MSD.
- Manuscripts will be considered for publication in the form of original articles, Case report, short communications, Letter to editor and review articles. The work should be original or a thorough by an authoritative person in a pertinent field.
- **Peer review process**
- All submissions will be reviewed anonymously by at least two independent referees. All manuscripts will be acknowledged upon presenting to the Journal office, provided that all stated requirements are met. Authors are encouraged to suggest names of three expert reviewers, but selection remains a prerogative of the Editor. The whole review process depends on receiving referees comments and revising the manuscripts based on these comments to the author. On receipt of the revised article from the author, and after final approving by referees, the letter of acceptance is issued to the author. Authors have the right to communicate to the editor if they do not wish their manuscript to be reviewed by a particular reviewer because of potential conflicts of interest. No article is rejected unless negative comments are received from at least two reviewers. **MSD employs double blind reviewing process:**



## Instruction for Authors

- **Ethical Rules and Rights**
- **Conflicts of interest**
- Conflicts of interest arise when authors, reviewers, or editors have interests that are not fully apparent and that may influence their judgments on what is published. They have been described as those which, when revealed later, would make a reasonable reader feel misled or deceived. (The Committee on Publication Ethics (COPE) states in its Guidelines on Good Publication Practice 2003).
- Authors should disclose, at the time of submission, information on financial conflicts of interest or other interests that may influence the manuscript. Authors should declare sources of funding for the work undertaken.
- **The Journal's Policy on Plagiarism**
- Any practice of plagiarism will not be tolerated by the journal regarding submitted manuscripts. Non-identifiable quoted segments of articles or close paraphrases from other author/s or even submitting the author's previously published work are known as the act of plagiarism by this journal unless proper use of quotations or paraphrasing with decent citation or referencing are in place. Heavy use of one or a couple of articles is discouraged, even if paraphrased fully. Advertent practice of plagiarism will abort reviewing process or later submission to this journal. All submitted articles will evaluate by *iThenticate* software belonged to cross check for stop any plagiarism and improve publication quality.
- **Statement of Human and Animal Rights**
- All submitted articles involving human experiments should be performed only in accordance with the ethical standards provided by the responsible committee of the institution and in accordance with the Declaration of Helsinki (as revised in Edinburgh 2000), available at <http://www.wma.net/en/30publications/10policies/b3/index.html>. Papers describing animal experiments can be accepted for publication only if the experiment conforms the National Institute of Health Guide (National Institute of Health Publications No. 80-23, Revised 1978) for the care and use of Laboratory Animals for experimental procedure. Authors must provide a full description of their anesthetics and surgical procedures. All manuscripts reporting the results of experimental investigations involving human subjects should include a statement confirming the informed consent was obtained from each subject or subject's guardian.
- **Humans:** When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.
- **Animals:** When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.
- All animal or human subjects should be used after approval of the experimental protocol by a local ethics committee.
- **Acknowledgements**
- Contributors: In acknowledgement section, name people for their contributions or their permission to reproduce their published material, to use their illustrations or provide information about them- try to fully name people who have helped from the conception of the idea to adoption of the hypothesis, to finalization of the study, etc., earnestly. Statement of financial support: Aside from the title page, state any financial or other relationships that might lead to a conflict of interest.
- **Copyright**
- After acceptance and publication; all ownership rights and Copyrights of the manuscript, passes to international journal of Medical Science and Discovery. Please complete copyright form and send via email to editor. [Download MSD Copyright Transfer and Author Consent Form](#)
- This work is licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](#).
- Copyright 2014: The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. All Rights reserved by international journal of Medical Science and Discovery.
- **Disposal of material**
- Once published, all draft copies of the manuscript, correspondence and artwork will be held at least for 6 months before disposal. Authors and Readers may find original PDF file of article on backup servers such as CLOKKS (<https://www.clockss.org/>)
- **Digital Object Identifier DOI**
- Once a manuscript is accepted for publication it will be provided with a registered DOI number following the acceptance decision. Manuscripts accepted for publication by the **MSD** will be published as ahead of print articles prior to the printing date of their scheduled issue. Corresponding author will be provided with a PDF Proof by the publisher once the production process of an accepted manuscript is over.

## Instruction for Authors

- **Article Processing Charge**
- MSD is a non-profit Scientific Journal Platform; however, it uses professional services such as Language Editing, DOI, domain and hosting, iThenticate Plagiarism or similarity Detection Software. All of these professional services are used for all the article processes and an inevitable cost arises with this.
- Unfortunately, like most open journals, fees of the publication with MSD are charged to Authors. Payment is under the responsibilities of corresponding Author(s). MSD does not charge any fee during the submission period. However, after the peer-review process, a non-refundable charge (100 USD ) for each accepted manuscript must be paid by the author(s) via MSD's official PayPal account. An invoice will be sent for each accepted manuscript to corresponding author(s).
- **Following with completion of payment procedure, the galley proof and acceptance letter of article will be send to authors for last check**
- Preparation of articles in PDF and HTML format is covered by Lycia Press Inc. (press.lycians.com) and Article Processing Charges paid to Lycia Press Inc. (press.lycians.com)
- **MSD revenue sources and Sponsorships**
- All costs arising from the publications are covered by the Sponsor Companies and Article Processing Charges. Sponsorship request evaluates by the MSD Journal Management Board and the **sponsor company logos** will be included on the back page of printed magazine and in the sponsor section of journal website

	Article Processing Charge (APC)	Discount %
Regular	100 USD	
for Editorial Board Members	70 USD	30%
for Affiliated Institution Members	80 USD	20%

- \*APC not includes Proofreading Services fee. Editor in Chief may direct the corresponding Author to Lycia Press, Language Office for Proofreading Service [www.lycians.com](http://www.lycians.com)
- 
- **References**
- Committee on Publication Ethics (COPE). (2011, March 7). Code of Conduct and Best-Practice Guidelines for Journal Editors. Retrieved from [http://publicationethics.org/files/Code\\_of\\_conduct\\_for\\_journal\\_editors\\_Mar11.pdf](http://publicationethics.org/files/Code_of_conduct_for_journal_editors_Mar11.pdf)
- World Association of Medical Editors (WAME). Principles of Transparency and Best Practice in Scholarly Publishing. <http://www.wame.org/about/principles-of-transparency-and-best-practice>

**Contents**

**Original Article**

**Evaluation of factors that affecting mortality in urgent redo-laparotomies**

**35-43**

Erdal Uysal, Serkan Kadir Turel, Efe Sezgin



## Evaluation of factors that affecting mortality in urgent redo-laparotomies

Erdal Uysal<sup>1\*</sup>, Serkan Kadir Turel<sup>2</sup>, Efe Sezgin<sup>3</sup>

### Abstract

**Objective:** The aim of this study was to investigate the factors that affect mortality in patients undergoing Urgent abdominal redo-laparotomies (UARLs), and to analyze the common indications and operative, demographic, and clinical characteristics in UARLs.

**Material and Methods:** Our study was designed as a retrospective, observational and multi-centric study. A total of 155 patients from two separate clinics undergoing urgent, unplanned redo-laparotomy were included in the study. The data obtained from all clinics were collected and the relations of the demographic, clinical and operational factors with the mortalities of primary surgery and multiple UARLs were analyzed.

**Results:** Mortality was observed in 42 (27%) patients. The most frequent causes of mortality were sepsis and multi-system organ failure in 23 (53.4%) patients. The relationships between the number of redo-laparotomy presence of blood transfusion, older age, classification of surgery and mortality were significant ( $p < 0.05$ ).

**Conclusion:** Sepsis and multi-organ failure were the most frequent cause of mortality in our study as well, with a rate of 53.4%. No significant relationship was observed between mortality and initial surgery under emergency conditions and presence of comorbidity. Redolaparotomies inevitable in some clinical situations. Since multiple redolaparotomies are associated with mortality, it is necessary to avoid complications during initial surgery to reduce UARLs. Major surgery operation UARLs in elderly people should be avoided. Finally, the surgeon should also make the UARLs decision at the right time.

**Key words:** Urgent, redo-laparotomy, mortality

### Introduction

Abdominal surgical interventions are applied for the treatment of benign and malignant diseases under urgent and elective conditions. Although laparoscopic abdominal interventions are widely preferred currently, laparotomy has been used frequently as well. The term redo-laparotomy or re-laparotomy is used for the laparotomies performed within 60 days following the primary surgery. Redo-laparotomies may be performed urgently, electively, planned or unplanned (1).

In our study, redo-laparotomies performed within 10 days following the initial surgery were described as urgent redo-laparotomies. Urgent abdominal redo-laparotomies (UARLs) have been considered as complicated and last option operations. The rates of mortality and morbidity of UARLs are quite high (2).

UARLs are generally performed due to the complications observed after the initial operation. The most common indications for UARLs include anastomosis leaks, intra-abdominal abscess,

peritonitis, mechanical intestinal obstruction, intra-abdominal hemorrhage, intestinal necrosis and intra-abdominal organ injuries (2).

Patients indicated for UARLs generally have a critical health situation. UARLs are still the most important step of the treatment for these patients (1,3). The mortality rates vary between 50 and 100% in cases with peritonitis that cannot be taken under control, namely those with sepsis and multiple system organ failure (4,5).

UARLs may be performed as on-demand surgery and planned. In planned UARLs, laparotomy is performed with pre-determined time intervals and thus the clinical situation is considered (6).

Both planned and on-demand surgeries are performed in the clinical centers in our study. UARLs may be performed once or multiple times according to clinical need.

Received 22-05-2017 Accepted 28-05-2017 Available Online 31-05-2017

1 Sanko University, Medical Faculty, Dept. of General Surgery, Gaziantep, TR

2 Afyon State Hospital, Dept. of General Surgery, Afyon, TR

3 Izmir Institute of Technology, Engineering Faculty, Department of Food Engineering, Izmir, TR

\* Corresponding Author: Erdal Uysal E-mail: [dredaluyisal@hotmail.com](mailto:dredaluyisal@hotmail.com) Phone: + 90342 211 65 69



Although UARLs are widely used, studies investigating the factors that affect mortality in patients undergoing UARLs are limited in number. We believe that a good analysis of the factors that affect mortality and avoiding these factors would reduce mortality rates after UARLs. The aim of this study was to investigate the factors that affect mortality in patients undergoing UARLs, and to analyze the common indications and operative-demographic-clinical characteristics in UARLs.

## Material and Methods

Our study was designed as a retrospective, observational and multi-centric study. A total of 155 patients undergoing urgent, unplanned redo-laparotomy among 2,830 patients undergoing abdominal surgery between January 2005 and July 2016, were included in the study. The participants were those who had undergone redo-laparotomy within 10 days following the initial surgery.

Two separate clinical centers were included in the study. The data obtained from all clinics were collected in a common electronic database. The data of the patients were obtained from the files and computer records according to the study protocol prepared previously by the study group.

In order to homogenize the data, the inclusion criteria were kept limited. Patients undergoing thoraco-abdominal surgery, laparoscopic surgery as the primary surgery and transplantations, those who had not undergone urgent redo-laparotomy, obstetric and pediatric patients, and patients treated via only interventional radiology or endoscopic interventions were excluded from the study.

Patients undergoing interventional radiology or endoscopic interventions prior to or after UARLs were not included either. Besides, superficial procedures not undergoing anesthesia were excluded from the study. The demographic characteristics, laboratory studies, radiographic examinations, operative reports, presence of concomitant adherent diseases such as malignancies, primary surgeries, postoperative complications, presence of multiple system organ failure, causes of mortality, clinical situations related to UAR, blood transfusions, duration of stay in emergency unit, duration of hospital stay, the interval between the laparotomies and the number of UARLs performed, were investigated.

The relations of the demographic and clinical factors with the mortalities of primary surgery and multiple UARLs were analyzed. The decision of UARLs were made according to the clinical situation of the patient, to radiological imaging results and to the laboratory findings.

The patients were followed-up for a minimum of 2 months following the operation, and mortalities in this period were included in the analysis. Information on

the operations and follow-up were provided by the surgeons who performed the primary operations and UARLs when necessary. The operations were performed by general surgeons experienced in gastrointestinal system surgeries.

The centers involved in the study are high volume and provide intensive care and surgery services at similar levels. General surgeons at centers participating in the study have a similar approach to primary and redo surgical decisions. All centers use the same diagnostic tools in UARLs decision. The antibiotics and inotropic agents administered to patients were determined in a multi-disciplinary manner according to the needs of the patients. This study is registered at [researchregistry.com](http://researchregistry.com) by the number ID [researchregistry1778](http://researchregistry.com)

## Statistical analysis

All statistical analyses are conducted by a statistician. Distribution of categorical factors (such as comorbidities, presence of blood transfusion, etc.) among mortality and no-mortality groups were compared by Chi-square tests. Mortality and no-mortality group means for the continuous variables (such as age) were compared by T-test. P-values less than 0.05 were considered as statistically significant. All statistical analyses were conducted by SAS/STAT version 9.3 (SAS Institute, Inc, Cary, North Carolina, USA)

## Results

A total of 155 patients undergoing UARL were included in the study. The median patient age was 63 (49,76). The ratio of female to male was 61/94 (0.64). The initial operations were urgent in 74 % of the patients. The number of redo-laparotomies was found to be  $1.18 \pm 0.58$  per patient. The median days (25%,75%) interval to first redo-laparotomy was 5 (2,7). The number of total comorbidity was 104. The most frequent comorbidity was heart disease with 50 (44%) patients (Table 1). The most frequent cause of UARLs was peritonitis in 62 (40%) patients, and the second most frequent cause was abscess in 26 (16.7%) patients. UARLs were performed with more than one indication in 17 (10.9%) of the patients. The decision of UARL was most frequently made via Physical examination in 139 (56 %) patients. In 93 (60%) of the patients, UARL was decided using more than one tool (Table 2).

The site of index surgery included the Biliary tract and gallbladder in 44 (28%) patients, colo-rectal in 34 (22%) and the small bowel in 31 (20%) patients, respectively. B group operations (Major surgery) were most frequently performed according to the classification of surgery in 114 (74%) patients. 137 (89%) patients had only one UARL, whereas 4 (3%) patients had over 3 redo-laparotomy (Table 3)

**Table 1:** Patient Characteristics

Total Patients n=155	%	
Sex (F/M)	61/94	
Age	63 (49,76)	
Emergency Operation	74	
Number of redo-laparotomy	1.18±0.58	
Median days Interval to first redo-laparotomy (25%,75%)	5 (2,7)	
Median days Hospital stay (25%,75%)	12 (9,19)	
Median days ICU stay (25%,75%)	9 (4,13)	
Comorbidite	<b>n</b>	<b>%</b>
• Heart disease	50	44
• Pulmonary disease	13	11,4
• Renal disease	14	12,3
• Diabetes	19	17
• Others	18	15,8
<b>Total (n)</b>	<b>104</b>	
Causes of death		
• Sepsis and MOF	23	53,4
• Intraabdominal hemorrhage	4	9,3
• Respiratory failure and pneumonia	8	18,6
• Cardiac	3	6,9
• Unknown	4	11,6
<b>Total (n)</b>	<b>42</b>	

M: male, F: female, ICU: intensive care unit, MOF: Multiorgan Failure,  
Comorbidite others: Autoimmune diseases, thyroid disease, hematological diseases, multiple comorbidite

**Table 2:** Indications of urgent Redo-laparotomy and decision tool

<b>Patients (n=155)</b>	n	%
<b>Indications</b>		
• Anastomotic leak	11	7
• Intra-abdominal hemorrhage	21	13,5
• Peritonitis	62	40
• Abscess	26	16,7
• Intestinal obstruction	21	13,5
• Bowel necrosis	6	3,8
• Abdominal dehiscence	7	4,5
• Other	18	11,6
<b>Total</b>	172	110,6
<b>Decision tool</b>		
Computed tomography/ultrasonography	85	34,2
Physical examination	139	56
Purulent discharge (wound) /drained content	16	6,4
Others	8	3,2
<b>Total</b>	<b>248</b>	<b>100</b>

Decision tool others: Multiple organ failure, positive blood culture, roentgenography, unexplained sepsis

**Table 3:** Operational characteristics

Patients (n:155)	n	%
<b>Site of index Surgery</b>		
• Pancreas	3	2
• Colo-rectal	34	22
• Small Bowel	31	20
• Biliary tract and gallbladder	44	28
• Gastro-duedonal	17	11
• Liver	8	5
• Appendix	16	10
• Spleen	2	1
<b>Classification of surgery*</b>		
• A	23	15
• B	114	74
• C	18	12
<b>The number of redo-laparotomy</b>		
• 1	137	89
• 2	11	7
• 3	3	2
• >3	4	3
<b>Initial operation</b>		
• Emergency	115	74
• Electively	40	26

A group operation : Featured, major surgery and initiatives B group operation: Major surgery, C group operation: Medium-sized operations. (\*Turkish Ministry of Health Annex- 9 List, 2015, classification of surgery list).

Mortality was observed in 42 (27%) patients. The most frequent causes of mortality were sepsis and multi-system organ failure in 23 (53.4%) patients. This was followed by Respiratory failure and pneumonia in 8 (18.6%) patients. The relationship between the number of redo-laparotomy and mortality was found to be significant ( $p=0.04$ ). Besides, a significant correlation was observed for blood transfusions, the number of redo-laparotomies, age, site of index surgery and classification of surgery ( $p<0.05$ ).

No significant relationship was observed between comorbidity, elective or emergency operations, indication at redo-laparotomy and mortality ( $p>0.05$ ).

No significant difference was observed between male and female patients with respect to mortality ( $P=0.85$ ) (Table 4).

Primary abdominal closure was performed on 118 (76%) patients subsequent to presumed source control. Secondary abdominal closure via mesh, and Bogota bag were performed on 37 (24%) patients. 46 (29.6%) patients recieved critical care support.

28 (18%) patients recieved ventilator support (over 48 hours). 30 (19.3%) patients recieved total paranteral nutrition support. All patients received paranteral antibiotics.

**Table 4:** Factors associated with mortality

	Mortality		
	Yes (n:42)	No (n:113)	p
Female	16(38)	45 (40)	0.84
Comorbidite (n)			<b>0.06</b>
• Heart disease	19 (50)	31 (41)	
• Pulmonary disease	7 (18)	6 (8)	
• Renal disease	4 (10)	10 (13)	
• Diabetes	4 (10)	15 (20)	
• Others	12 (30)	6 (8)	
Emergency/ Electively operations	29/13	86/27	<b>0.37</b>
Presence of blood transfusion	36 (86)	53 (47)	<b>&lt; .0001</b>
The number of blood transfusion			<b>0.29</b>
• 1 Unit	7 (21)	9 (18)	
• 2 Unit	17 (52)	31 (61)	
• 3 Unit	6 (18)	4 (8)	
• 4 Unit	2 (6)	1 (2)	
• >4 Unit	1 (3)	6 (12)	
Classification of surgery*			<b>0.0002</b>
• A	13 (31)	10 (9)	
• B	29 (69)	85 (75)	
• C	0 (0)	18 (16)	
The number of redo-laparotomy			<b>0.04</b>
• 1	32 (76)	104 (92)	
• 2	6 (14)	5 (4)	
• 3	1 (2)	2 (2)	
• > 3	3 (7)	1 (0.9)	
Site of index Surgery			<b>0.0005</b>
Pancreas	3 (7)	0 (0)	
Colo-rectal	9 (21)	25 (22)	
Small Bowel	11 (26)	20 (18)	
Biliary tract and gallbladder	8 (19)	36 (32)	
Gastro-duedonal	10 (24)	7 (6)	
Liver	1 (2)	7 (6)	
Appendix	0 (0)	16 (14)	
Spleen	0 (0)	2 (2)	
Indication at redo-laparotomy			<b>0.54</b>
Anastomotic leak	5 (12)	6 (5)	
Intra-abdominal hemorrhage	6 (14)	15 (13)	
Peritonitis	19 (45)	43 (35)	
Abscess	5 (12)	21 (18)	
Intestinal obstruction	6 (14)	15 (13)	
Bowel necrosis	4 (9)	2 (2)	
Abdominal dehiscence	2 (5)	5 (4)	
Other	5 (12)	13 (12)	
Age	71.5 (61.0/81.0)	60 (45,73)	<b>0.002</b>
Median days Interval to first redo-laparotomy (25%,75%)	4 (2,6)	5 (2,7)	<b>0.61</b>

A group operation: Featured, major surgery and initiatives, B group operation: Major surgery C group operation: Medium-sized operations. (\*Turkish Ministry of Health Annex- 9 List, 2015, classification of surgery list) The results were given as mean±standard deviation. Site of index Surgery others: Abdominal Wall, multiple site

## Discussion

UARLs are generally performed due to the complications observed following the initial operation. Anastomosis leaks, intra-abdominal abscess, peritonitis, mechanical intestinal obstruction and intra-abdominal hemorrhage are the main indications for UARLs. The incidence of UARLs varies according to the initial operations. The incidence of UARLs has been reported as 1-4.4% in different studies (2,7,8). In our study, the incidence of UARLs was 5%.

Different clinical centers report different orders for the frequency of causes of UARLs. In the study of Unalp et al., the most frequent causes of UARLs were intestinal repair or anastomosis leaks in 51.85% of the patients, followed by intra-abdominal hemorrhage in 18.51% and intra-abdominal abscess in 9.87%. Koirala R et al. , have reported intra-abdominal hemorrhage, intraabdominal abscess and collections as the most frequent causes of UARLs in 34.2% and 29.6% patients, respectively (1,2). Koirala R et al. have related the high rate of inta-abdominal hemorrhage in their study to the high rate of hepatic and pancreatic surgeries (2). In our study, UARLs were most frequently performed due to peritonitis in 40 % of the patients, intra-abdominal hemorrhage in 13.5%, intra-abdominal abscess in 16.7 % and mechanical intestinal obstruction in 13.5 %. Intra-abdominal abscesses are common. Residual intra-abdominal abscesses may be observed in gastrointestinal perforations or following the surgical treatment of acute appendicitis. Intra-abdominal abscesses may additionally be observed in anastomosis leaks of the gastrointestinal system. The majority of intra-abdominal abscesses may be drained by interventional radiology. However, in presence of diffuse intra-abdominal abscess, in situations where generalized peritonitis accompanies the abscess and where drainegae is technically impossible, surgical drainage may be preferred. In our stuy, patients for whom intra-abdominal abscess drainage could not be performed by interventional radiology were evaluated. Thus, the rate of intra-abdominal abscess-related UARLs were found to be high. Intra-abdominal hemorrhages form the first order in patients who had undergone multiple UARLs in our study, with a rate of 13.5%. The cause of increased intra-abdominal hemorrhage in initial UARLs may be related to insufficient hemostasis, impaired coagulation in patients, insufficient amount of coagulation factors and massive blood transfusion.

UARLs were most frequently performed following biliary tract and gallbladder surgery in our study, with a rate of 28%. The most frequent causes of UARLs in biliary tract and gallbladder surgery were found to be intra-abdominal hemorrhage and biliary leaks, respectively. The high rate of initial biliary tract and gallbladder surgery was believed to be related to the increase in the number of UARLs. Furthermore,

studies report high rates of intra-abdominal hemorrhage and anastomosis leaks following pancreas surgery (9,10). Increased rates of UARLs may be related to the increased rate of complications. The most frequent causes of UARLs in patients undergoing colo-rectal surgery were found to be anastomosis leaks, intra-abdominal abescens and peritonitis, respectively. In a study evaluating re-laparatomies, the colon was reported to be the major source of intra-abdominal infection leading to peritonitis (11). Anastomosis leaks, intra-abdominal abscess and peritonitis were mostly observed in patients undergoing colorectal surgery in our study.

UARL was performed due to anastomosis leak in 7 % of the patients in our study. The most frequent anastomosis leaks were observed in colo-colic, colo-rectal, oesophago-jejuno-stomy and pancreatico-jejuno-stomy anastomoses, respectively. The last anastomosis leak was observed in the anastomoses performed between the small intestines. Anastomosis leaks lead to generalized peritonitis, sepsis, fluid and electrolyte loss, multi-system organ failure, and may result in death. In some studies, high mortality rates have been reported following UARLs performed due to peritonitis. On the other hand, there are studies reporting reduced mortality rates following planned re-laparatomies since they provided effective irrigation and drainage (11-14). Consideration of UARLs has been suggested in the treatment of uncontrolled intra-abdominal infection and multi-system organ failure (15).

Mortality was mostly observed in relation to multi-system organ failure and sepsis developing following anastomosis leaks in our study. Despite multi-redo-laparatomies performed on the patients, high mortality rates were encountered. In the study of Sautner T et al., re-laparatomies performed on patients with abdominal sepsis were reported to increase the inflammatory response, and the increased inflammatory response was reported to increase the mortality rates (12). In another study, re-laparotomy was reported to change the multi-system organ failure into an irreversible situation when the treatment to be performed with re-laparotomy was not properly selected (16). Purulent, fecal and biliary peritonitis may continue at a rate of 9-41% despite redo-laparatomies (17). The reason for the sepsis and mortality that could not be controlled despite UARL in our study may be the peritonitis, increased inflammatory response and insufficient surgery in the first UARL.

In addition to the sufficient surgical treatment in UARL, the timing of the surgery is also important. A delayed surgical intervention on the intra-abdominal septic focus may lead to sepsis and multi-organ failure. Therefore, early diagnosis and treatment will reduce the mortality and morbidity (7,18). Mortality rates may be reduced from 46% to 26.5% with early diagnosis and treatment (19).

In our study, the Median interval to first redo-laparotomy was 5 (2,7) days in patients without mortality; it was 4 (2,6) days in patients with mortality. The difference between the two groups was not statistically significant. Despite the advances in the surgical techniques and intensive care conditions, the mortality rates after UARLs have been reported to be as high as 61.5 % (1). In a study evaluating UARLs, the mortality rate was found to be 33% (2). It was reported to be 37.03% in the study of Unalp et al. (1). In our study, the mortality rate was 27%. Our findings consistent with the findings in the literature.

Ching SS et al. have classified the risk of mortality in UARLs as low, moderate and high. Accordingly, wound separation was in the low risk group, and anastomosis leaks were in the high risk group (9). Unalp et al. have reported mesentery artery embolus, intestinal perforation and anastomosis failure in the high mortality risk group, and intra-abdominal infection and abscess in the moderate and low risk groups, respectively (1). Koirala R et al. have reported intra-abdominal hemorrhages as diseases with the highest mortality (2). In the same study, fecal fistula without evidence of anastomotic failure was reported to be the disease with the lowest mortality. In our study, sepsis and multi-system organ failure was the most common cause of mortality with a rate of 53.4 %. It was followed by respiratory failure and pneumonia with a rate of 18.6 %, and respiratory failure and intraabdominal hemorrhage at a rate of 9.3 %. However, no significant relationship was observed between the indication for redo-laparotomy and the mortality ( $p=0.54$ ).

High mortality rates have been reported in UARLs performed subsequent to gastrointestinal system surgeries (20). Mortality rates were high among patients undergoing gastrointestinal system surgeries. Significant relationship was observed between the site of initial surgery and the mortality in our study ( $p=0.0005$ ).

It has been reported that UARLs performed in unexplained sepsis resistant to medical treatment reduced the mortality. Holzheimer and Gathof have demonstrated that re-laparotomy reduced the mortality rates from 67% to 37.5% in persistent sepsis (21). However, it is impossible to determine the septic foci in all cases. Determining the septic focus is possible in only 17% of the patients (22). In our study, UARL was performed on 5 (3.2%) patients due to unexplained resistant sepsis. The mortality rate in this group was 20 %. This rate constituted 2.3 % of the total mortality.

A significant relationship has been reported between the number of redo-laparotomies and the mortality in previous studies. It has been reported in the study of Rygachev GP et al. that the mortality rates were significantly higher in multiple re-laparotomies compared to single re-laparotomies (23). In the study

of Koirala R et al. , the mortality rates were reported to be 23.6% in single relaparotomies and 61.2% in multiple re-laparotomies (1). Rygachev GP et al. have found significant differences between single and multiple redo-laparotomies with regard to mortality rates (23). The patients may undergo multiple redo-laparotomies due to an improper initial redo-laparotomy. In our study, the mean number of UARLs in patients with mortality was  $1.18\pm 0.58$  per patient. The difference between the two groups was statistically significant ( $p=0.04$ ). The presence of a residual infection, insufficient treatment in the initial UARL, insufficient managing of newly developed complications and reduced patient reserve may be responsible for the high mortality rates. The higher incidence of multi-organ failures in elderly patients supports this finding (24). Unalp et al. have reported the etiology rather than the number of redo-laparotomies as the responsible factor for increased mortality (1).

Postoperative intra-abdominal hemorrhage is an important cause of UARLs. Bleeding may originate from a major vascular structure or a small vascular structure. Intra-abdominal hemorrhage may originate from the edges of the drain, the incision line, or from the upper or lower gastrointestinal system. UARLs may be necessary in large volume bleedings that impair the hemodynamics of the patient. Disseminated intravascular coagulopathy may also develop in delayed bleedings that necessitate recurrent blood transfusions. UARL may also be necessary for these patients (1). The rate of hemorrhage in abdominal surgeries has generally been reported to be between 0.9 and 4.7% (25). In another study, the rate of postoperative intra-abdominal hemorrhages was reported to be between 3.3 and 19% in patients undergoing UARL (26,27). The rate of hemorrhage following abdominal surgical interventions was reported to be 0.1% in the study of Kononov AG et al. The reason for the low rate of intra-abdominal hemorrhage in the study of Kononov AG et al. was related to the early diagnosis and good preoperative preparation of the patients with the risk of bleeding (28). Rate of UARLs was found to be 1% in our study, since intra-abdominal hemorrhage was observed in all abdominal interventions. This rate is consistent with the findings in the literature. Postoperative intra-abdominal hemorrhages were related to improper and insufficient hemostasis in the initial surgery with a rate of 72.2% (28). In postoperative intra-abdominal hemorrhages, delayed diagnosis-related mortality rate was found to be 18.4 - 33.33% (7,29). In the study of Koirala R et al., intra-abdominal hemorrhage-related mortality rate was 42.4%. This high mortality rate compared to the findings in the literature was suggested to be due to high-volumed liver and pancreas surgeries (28). The rate of intra-abdominal hemorrhage related mortality in our study was 9.3 %, and this was compatible with the findings in the literature.

One of the important causes of UARLs is postoperative mechanical intestinal obstructions. It has been reported in different series that 5-60% of redo-laparotomies were performed due to intestinal obstructions (2). This rate was 5% in the study of Unalp et al. and 6.7% in the study of Koirala R et al. (1,2). Postoperative adhesions are the most important causes of obstructions (30). Other causes include intra-abdominal sepsis, abdominal dehiscence, previous femoral or other inguinal hernias (31). The frequency of mechanical intestinal obstructions developing in the early postoperative period is less than 1% (32). These patients may be recommended surgical decompression, nasogastric decompression or conservative approach (33). In our study, the rate of UARL due to mechanical intestinal obstruction was 13.5%. This rate was consistent with the findings in the literature. The conservative approach or UARL for mechanical intestinal obstruction is still a debate. There is no consensus on the timing of re-laparotomy either. In the study of Unalp et al., the mean redolaparotomy interval was 4 days, whereas it was 12.7 days in the study of Koirala R et al. (1,2). Median interval to first redo-laparotomy was 5 (2,7) days in our study. The longer interval time may be primarily due the surgeons selecting a more conservative approach. The mortality rates in mechanical intestinal obstruction related redo-laparotomies was found to be approximately 10% (34). The mortality rates in patients undergoing redo-laparotomies due to mechanical intestinal obstructions was found to be as 14.2 % in our study.

Different centers report different causes of mortality following UARLs. In the study of Koirala R et al., the most frequent causes of mortality were sepsis ve multi-organ failure in 64% of the patients. In the study of Oddeke VR, Haluk R and Wain MO, the sepsis and multi-organ failure were reported to be the most frequent cause of mortality as well (1,22,31). Sepsis and multi-organ failure were the most frequent cause of mortality in our study as well, with a rate of 53.4 %. This result was consistent with the findings in the literature.

APACHE II reflects the Acute Physiology and Chronic Health situation, and helps evaluate the severity of the disease. There is a relationship between high score and mortality. In the study of Pusajó JF et al. on postoperative intra-abdominal sepsis requiring re-operation, the APACHE II score was found to be significantly higher in the mortality group (3). Hinsdale JG et al. have reported that patients undergoing re-laparotomy due to intra-abdominal sepsis and multi-organ failure demonstrated significantly higher mortality rates (8). Multi-organ failure was also high in the mortality group in our study. No significant relationship was found between the initial surgery performed under emergency conditions and presence of comorbidity, and the

mortality in patients undergoing UARL. This finding is consistent with the literature (1,2).

We found a significant correlation between the blood transfusions and mortality in patients undergoing UARL. Blood transfusion may lead to coagulation disorders or DIC. The increased mortality in our study may be directly related to the complications of blood transfusion. On the other hand, it may be related to the acidosis that develop as a result of hemorrhage, and tissue hypoxia. Thus, blood transfusions may be considered as an indirect indicator of a patient whos is in a critical situation.

### Study limitations

Although, there are a few limitations in our study, this research was a multi-center study and had rather wide series, more parameters could not be compared since it was a retrospective study. In order to understand the relationship between the surgeries and mortality, it may be necessary to evaluate each surgery separately. Initial UARLs, risk factors in UARLs performed for the second, third and more than three times, and indications at redo-laparotomy may be evaluated separately. While many operations were performed, the decision-making of UARLs may vary among the two centers, even if the same diagnostic tool was used. Factors affecting mortality following UARLs should be further investigated in prospective studies including larger series.

### Conclusion

Sepsis and multi-organ failure were the most frequent cause of mortality in our study with a rate of 53.4 %. No significant relationship was observed between mortality and initial surgery under emergency conditions and presence of comorbidity. Redolaparotomies are inevitable in some clinical situations. Since multiple redolaparotomies are associated with mortality, the first redolaparotomy is very important. It is necessary to avoid complications during initial surgery to reduce UARLs and mortality. The surgeon should also make the UARLs decision at the right time.

**Conflict of Interest:** The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Author's Contributions:** **EU, SKT:** Collecting of patients data, Patient examination and operation, writing and revision of article, **EF:** Statistical analysis of findings.

**Ethical issues:** All Authors declare that Originality of research/article etc... and ethical approval of research, and responsibilities of research against local ethics commission are under the Authors responsibilities. The study was conducted due to defined rules by the Local Ethics Commission guidelines and audits.

## References

1. Koirala R, Mehta N, Varma V, Kapoor S, Kumaran V, Nundy S. Urgent Redo-Laparotomies: Patterns and Outcome-A Single Centre Experience. *Indian J Surg* 2015;77(3):195-9.
2. Haluk RU, Erdinc K, Haldun K, Ahmet B, Mustafa P, Mehmet AO. Urgent abdominal re-explorations. *World J Emerg Surg*. 2006;1:10.
3. Pusajó JF, Bumaschny E, Doglio GR, et al. Postoperative intra-abdominal sepsis requiring reoperation. Value of a predictive index. *Arch Surg* 1993;128(2):218-22.
4. Fry DE, Garrison RN, Neitsch RC, Calhoun K, Polk HC. Determinants of death in patients with intra-abdominal abscess. *Surgery* 1980; 88(4):517-523.
5. Christou NV, Barie PS, Dellinger EP, Waymack JP, Harlan H. Surgical Infection Society Intra-abdominal Infection Study. *Arch Surg* 1993;128(2):193-199.
6. Butler JA, Huang J, Wilson SE. Repeated laparotomy for postoperative intra-abdominal sepsis. An analysis of outcome predictors. *Arch Surg* 1987;122(6):702-6.
7. Ching SS, Muralikrishnan VP, Whiteley GS. Relaparotomy: a fiveyear review of indications and outcome. *Int J Clin Pract* 2003; 57(4):333-337.
8. Hinsdale JG, Jaffe BM. Re-operation for intra-abdominal sepsis. Indications and results in modern critical care setting. *Ann Surg* 1984;199(1):31-6.
9. Nakayama Y, Konishi M, Gotohda N, et al. Comparison of postoperative early and late complications between pancreas-sparing duodenectomy and pancreatoduodenectomy. *Surg Today* 2017;47(6):705-711.
10. Loveček M, Skalický P, Köcher M, et al. Postpancreatectomy haemorrhage (PPH), prevalence, diagnosis and management. *Rozhl Chir* 2016;95(9):350-357.
11. Teichmann W, Wittmann DH, Andreone PA. Scheduled reoperations (etappenlavage) for diffuse peritonitis. *Arch Surg*. 1986;121(2):147-52.
12. Sautner T, Gotzinger P, Redl-Wenzel EM, et al. Does reoperation for abdominal sepsis enhance the inflammatory host response? *Arch Surg* 1997;132(3):250-5.
13. Wittmann DH, Aprahamian C, Bergstein JM. Planned relaparotomy: advanced diffuse peritonitis managed by planned multiple laparotomies utilizing zippers, slide fastener, and Velcro analogue for temporary abdominal closure. *World J Surg*. 1990;14(2):218-26.
14. Billing A, Frohlich D, Mialkowskyi O, Stokstad P, Schildberg FW. Treatment of peritonitis with staged lavage: prognostic criteria and course of treatment. *Langenbecks Arch Chir* 1992;377(5):305-13.
15. Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: clinical features of a complex nosocomial infection. *World J Surg* 1998;22(2):158-63.
16. Marshall JC, Christou NV, Horn R, Meakins JL. The microbiology of multiple organ failure. The proximal gastrointestinal tract as an occult reservoir of pathogens. *Arch Surg* 1988;123(3):309-15.
17. Mulier S, Penninckx F, Verwaest C et al. Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. *World J Surg* 2003;27(4):379-384.
18. Mulari K, Leppaniemi A. Severe secondary peritonitis following gastrointestinal tract perforation. *Scand J Surg*. 2004;93(3):204-208.
19. Zavermyi LG, Poida AI, Melik VM, et al. Prognosis in the outcome of relaparotomy. *Klin Khir* 1992;(8):12-16.
20. Oddeke VR, Cecilia WM, Kimberly RB. Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis: a randomized trial. *JAMA* 2007;298(8):865-872.
21. Holzheimer RG, Gathof B. Re-operation for complicated secondary peritonitis – how to identify patients at risk for persistent sepsis. *Eur J Med Res* 2003;8(3):125-134.
22. Hutchins RR, Gunning MP, Lucas DN, Allen-Mersh TG, Soni NC. Relaparotomy for suspected intraperitoneal sepsis after abdominal surgery. *World J Surg* 2004; 28(2):137-141.
23. Rygachev GP, Nekhaev AN, Kerez PI, Kremen VE. Relaparotomy in the treatment of generalized postoperative Peritonitis. *Khirurgiia* 1997;(1):45-48.
24. Harbrecht PJ, Garrison RN, Fry DE. Early urgent relaparotomy. *Arch Surg* 1984; 119(4):369-374.
25. Tasu JP, Vesselle G, Herpe G, et al. Postoperative abdominal bleeding. *Diagn Interv Imaging* 2015;96(7-8):823-31.
26. Tera H, Aberg C. Relaparotomy. A ten-year series. *Acta Chir Scand* 1975;141(7):637-644.
27. Krivitskii D, Shuliarenko VA, Babin IA. Indications for relaparotomy. *Klin Khir* 1990; (1):18-21.
28. Kononov AG, Sotnicenko BA, Makarov VI. Relaparotomy for intra-abdominal hemorrhage. *Acta Chir Iugosl* 1990;37(1):65-73.
29. Mamchich VI, Shaprinskii VA, Palienko PK. Intraabdominal hemorrhage after surgery on the abdominal organs requiring relaparotomy. *Klin Khir* 1992;(8):31-34.
30. Leshchenko IG, Panov FI. Relaparotomy for postoperative mechanical intestinal obstruction in abdominal injuries. *Vestn Khir Im I I Grek* 1991;146(4):88-91.
31. Wain MO, Sykes PA. Emergency abdominal re-exploration in a district general hospital. *Ann R Coll Surg Engl*. 1987;69(4):169-74.
32. Zavermyi LG, Poida AI, Tarasov AA, Mel'nik VM, Nadeev SS. Indications for relaparotomy in acute postoperative intestinal obstruction. *Klin Khir* 1992; (4):4-7.
33. Ellozy SH, Harris MT, Bauer JJ, Gorfine SR, KreeI I. Early postoperative small-bowel obstruction: a prospective evaluation in 242 consecutive abdominal operations. *Dis Colon Rectum* 2002;45(9):1214-1217.
34. QuatromoniJC, RosofIL, HallsJ, Yellin AE. Early postoperative small bowel obstruction. *Ann Surg*1980; 191(1):72-4.





# MSD

Medical Science & Discovery



International Journal of  
Medical Science and Discovery  
Open Access Scientific Journal  
ISSN: 2148-6832  
Lycia Press LONDON U.K.  
[www.medscidiscovery.com](http://www.medscidiscovery.com)



lycians

[www.lycians.com](http://www.lycians.com)